Skip to main content
Toggle navigation
Search
Home
Central Nervous System
Home
Central Nervous System
Central Nervous System
Type here to filter the list
(6) Characteristics of Medicare Part D eligible patients at risk for qualifying for the concurrent use of opioids and benzodiazepines Star Measure
(50) Real-World Discontinuation Risk and Adverse Events with Anti-Amyloid Therapies in Patients with Alzheimer’s Disease
(51) Economic and Clinical Impact of Dual Orexin Receptor Antagonists Versus Zolpidem in Medicare Part D Beneficiaries with Chronic Insomnia
(52) Impact of Medication Adherence on Clinical and Economic Outcomes in Multiple Sclerosis: A Scoping Review of Real-World Evidence
(53) Real-World Patterns in Preventive CGRP Use Pre and Post AHS 2024 Position Statement Update in a Commercially Insured Population
(54) Methods for dopamine delivery across the blood-brain barrier in treating Parkinson’s disease: a systematic literature review
(56) Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
(57) Tuberous sclerosis complex–associated neuropsychiatric disorders (TAND) outcomes following adjunctive cannabidiol (CBD) treatment: 3-month analysis of the open-label phase 3b/4 trial EpiCom
(58) Efficacy and Safety of Symbravo® (MoSEICTM meloxicam and rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Trial
(59) Indirect treatment comparison for early efficacy of VMAT2 inhibitors for tardive dyskinesia and chorea associated with Huntington’s disease
(60) Valbenazine improves the impacts and symptoms of tardive dyskinesia: results from the phase 4 kinect-pro study
(61) Epidemiology, Patient Characteristics, Real-World Treatment Patterns, and Outcomes for Patients with Multifocal Motor Neuropathy (MMN).
(62) Efficacy and safety of ecopipam for Tourette syndrome: results from a phase 3, randomized, double-blind, placebo-controlled withdrawal trial
(63) Employment status and care requirements among people with amyotrophic lateral sclerosis in the United States
(64) Managed care approaches to address unmet patient needs in multiple sclerosis (MS): AMCP Market Insights Program
(65) Use of Health Services by People Living with Angelman Syndrome
(66) Analysis on the net costs of administering a prior authorization policy for onabotulinumtoxinA in the chronic migraine population
(68) Healthcare resource utilization and costs in patients with multiple sclerosis treated with ofatumumab vs ocrelizumab
(69) Effect of managed care educational interventions in multiple sclerosis during a period of advancing innovation
(70) Managed care approaches to address unmet patient needs in idiopathyic hypersomnia (IH): AMCP Market Insights program
(71) Healthcare resource use and clinical burden in narcolepsy: An analysis of the All of Us research program
(72) Treatment patterns among patients with newly diagnosed epilepsy in the United States
(73) Persistence with Eptinezumab and Other Preventive Treatments for Chronic Migraine in the United States: Results of a Retrospective, Observational, Cohort Study
(74) Longitudinal assessment of treatment costs in patients with spinal muscular atrophy receiving disease-modifying therapies
(75) What aspects of treatment are important to people living with Neuromyelitis Optica Spectrum Disorder (NMOSD)? A qualitative study
(76) Retention Rates Across Clinical Trials of Anti-CGRP Monoclonal Antibodies for Migraine Prevention
(77) Productivity losses among individuals diagnosed with narcolepsy or idiopathic hypersomnia
(78) Sustained Reductions in Monthly Headache Days with Long-Term Eptinezumab Treatment for Chronic Migraine: Post-Hoc Analysis of the Phase 3 PREVAIL Study
(79) Prevalence and Incidence of Generalized Anxiety Disorder Among Adults in the United States
(80) Healthcare resource utilization and costs among individuals with narcolepsy and idiopathic hypersomnia in the United States
(81) The Global Societal Burden of Alzheimer’s Disease by Severity: A Targeted Literature Review
(82) Impact of Specialty Referral Timing on Treatment Start and Cost Outcomes in Amyotrophic lateral sclerosis (ALS): A Real-World Claims Analysis
